This study provides new mechanistic insights into how epalrestat exerts a neuroprotective effect and attenuates the pathogenesis of stroke, implicating the AR/AKT/mTOR pathway as a potential therapeutic target for stroke patients. This evidence concerns the gene AKT1 and stroke disorder.